CSF3 and autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation: Moreover, the observation that Plcg2S707Y/+ mice with established disease can be completely rescued by anti-G-CSF treatment, without inducing neutropenia, may offer a more appealing therapeutic strategy for individuals with APLAID in the future.